Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamifeport - CSL Vifor

Next Previous
X
Search
Drug Profile

Vamifeport - CSL Vifor

Alternative Names: Vamifeport hydrochloride - CSL Vifor ; VIT-2763; VIT-2763 3HCl; VIT-2763 trihydrochloride; VIT-2763-PM1

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vifor Pharma
  • Developer CSL Vifor
  • Class Amides; Amines; Anti-inflammatories; Benzimidazoles; Fluorobenzenes; Oxazoles; Pyridines; Small molecules
  • Mechanism of Action Metal-transporting-protein-1-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Beta-thalassaemia; Iron overload; Sickle cell anaemia
  • Phase I Unspecified

Most Recent Events

  • 24 Mar 2024 CSL Vifor completes a phase-II clinical trials in Sickle cell anaemia in USA, Greece, Lebanon, United Kingdom, France (PO) (NCT04817670)
  • 10 Nov 2022 Vifor Pharma withdrawn phase II trial in Beta-thalassemia in USA, Italy, Bulgaria, Greece, Israel due to strategic reasons (NCT04938635) (EudraCT2021-001639-23)
  • 02 Aug 2022 Vifor Pharma has been acquired by CSL and renamed to CSL Vifor

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top